The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Cited by
Sorted by citations
Items 701–800 of 1,001
Hu, J., Wang, Z., Liao, C., Chen, Z., Kang, F., Lin, C., Lin, T.-S., Huang, L., Tian, Y., & Chen, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958960 · Cited by 16
Dalal, P., Patel, N. P., Feinstein, M. J., & Akhter, N. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132927 · Cited by 17
Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review
Strati, P., Gregory, T. K., Majhail, N. S., & Jain, N. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00819 · Cited by 18
Ryan, C. E., Zon, R. L., Redd, R. A., Fisher, D. C., Shouval, R., Kumar, A. A., Crombie, J. L., Sadrzadeh, H., Kim, A. I., Nayak, L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19037 · Cited by 16
Self-citationOutcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson, J. N., Handorf, E. A., Villa, D. R., Gerrie, A. S., Chapani, P., Li, S., Medeiros, L. J., Wang, M. L., Cohen, J. B., Churnetski, M. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010757 · Cited by 16
Self-citationAllogeneic CAR T Cell Therapy for Cancer
Sasu, B. J., Lauron, E. J., Schulz, T. F., Cheng, H., & Sommer, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-023316 · Cited by 16
Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer
Somboonpatarakun, C., Phanthaphol, N., Suwanchiwasiri, K., Ramwarungkura, B., Yuti, P., Poungvarin, N., Thuwajit, P., Junking, M., & Yenchitsomanus, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111631 · Cited by 20
Applications of Flow Cytometry in Drug Discovery and Translational Research
Ullas, S., & Sinclair, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073851 · Cited by 17
Pola, R., Pokorná, E., Vočková, P., Böhmová, E., Pechar, M., Karolová, J., Pankrác, J., Šefc, L., Helman, K., Trněný, M., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.014 · Cited by 16
Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., van Besien, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001235 · Cited by 16
Othman, T. A., Herrera, A. F., & Mei, M. G. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00603-3 · Cited by 16
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
Atrash, S., & Moyo, T. K. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242018 · Cited by 16
Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M. H., Kahl, B. S., Jerkeman, M., Kharfan‐Dabaja, M. A., Locke, F. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.001 · Cited by 17
Self-citationAhmed, G., Bhasin-Chhabra, B., Szabó, A., Shah, N. N., Longo, W. E., Dhakal, B., Chhabra, S., D’Souza, A., Fenske, T. S., & Hamadani, M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.007 · Cited by 16
Clinical development of cell therapies for cancer: The regulators' perspective
Exley, A., Rantell, K. R., & McBlane, J. W. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.006 · Cited by 16
CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases
Yang, Z., Liu, Y., & Hai, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122556 · Cited by 16
Russell, G. C., Hamzaoui, Y., Rho, D., Sutrave, G., Choi, J. S., Missan, D., Reckard, G. A., Gustafson, M. P., & Kim, G. B. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.03.484 · Cited by 15
Traynor, R., Vignola, I., Sarkar, S., Procházková, M., Cai, Y., Shi, R., Underwood, S., Ramanujam, S., Yates, B., Silbert, S. K., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.11.013 · Cited by 15
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
Phanthaphol, N., Somboonpatarakun, C., Suwanchiwasiri, K., Yuti, P., Sujjitjoon, J., Augsornworawat, P., Baillie, G. S., Junking, M., & Yenchitsomanus, P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06453-y · Cited by 15
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
Eyre, T. A., Cheah, C. Y., Sarkozy, C., Kumar, A. A., & Gouill, S. L. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00146 · Cited by 18
Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Wronski, M., Wesselingh, R., Kazzi, C., Seery, N., Ko, K., Li, J. J., Tan, T., Simpson, T., Abbott, C., Fleming, S. A., et al. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578717 · Cited by 16
CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
Narkhede, M. S., Mehta, A., Ansell, S. M., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5546 · Cited by 19
Sun, K.-H., Wong, Y.-T., Cheung, K. M., Yuen, C. M., Chan, Y.-T., Lai, W.-Y. (., Chao, C. (., Fan, W.-S., Chow, Y.-K., Law, M. F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020409 · Cited by 15
Emerging drug targets for colon cancer: A preclinical assessment
Crutcher, M. M., Baybutt, T. R., Kopenhaver, J. S., Snook, A. E., & Waldman, S. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2039119 · Cited by 15
Sun, Z., & Liu, M. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.009 · Cited by 16
Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud
Muthuvel, M., Srinivasan, H., Louis, L., & Martin, S. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155920 · Cited by 16
Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy
Gill, J. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220623152350 · Cited by 16
Akhuba, L. G., Tigai, Z. G., & Shek, D. (2022) · Biomedicines · doi:10.3390/biomedicines10123196 · Cited by 15
Highlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer
He, Q., Hu, H., Yang, F., Song, D. E., Zhang, X., & Dai, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114609 · Cited by 16
Younes, S. F., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D. M., Johnsrud, A. J., Majzner, R. G., Miklos, D. B., Frank, M. J., & Natkunam, Y. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100256 · Cited by 15
Self-citationBranella, G. M., Lee, J. Y., Okáľová, J., Parwani, K. K., Alexander, J. S., Arthuzo, R. F., Fedanov, A., Yu, B., McCarty, D., Brown, H. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294555 · Cited by 15
Qian, H., Yang, X., Zhang, T.-T., Zou, P., Zhang, Y., Tian, W., Mao, Z., & Wei, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27198 · Cited by 15
Update of Natural Products and Their Derivatives Targeting Epstein–Barr Infection
Pennisi, R., Trischitta, P., Costa, M. D. A., Venuti, A., Tamburello, M. P., & Sciortino, M. T. (2024) · Viruses · doi:10.3390/v16010124 · Cited by 15
Thirumalaisamy, R., Vasuki, S., Sindhu, S., Mothilal, T. M., Srimathi, V., Poornima, B., Bhuvaneswari, M., & Hariharan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01090-0 · Cited by 17
Xin, X., Zhu, X., Yang, Y., Wang, N., Wang, J., Xu, J., Wei, J., Huang, L., Zheng, M., Xiao, Y. Q., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00940-y · Cited by 16
Denlinger, N., Song, N., Zhang, X., Jeon, H., Peterson, C. M., Wang, Y., Reynolds, K., Bolz, R. M., Miao, J., Song, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012073 · Cited by 15
Self-citationOvercoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 17
Monick, S. E., & Rosenthal, A. C. (2024) · Cancers · doi:10.3390/cancers16101881 · Cited by 16
Lorenc, R., Shouval, R., Flynn, J. R., Devlin, S. M., Saldia, A., Luna, A., Corona, M., Tomás, A. A., Cassanello, G., Leslie, L. A., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.027 · Cited by 15
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ok, C. Y., Navsaria, L. J., Nastoupil, L. J., Lee, H. J., Tang, G., Yin, C. C., Badillo, M., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26109 · Cited by 15
Self-citationKarschnia, P., Struebing, F. L., Teske, N., Blumenberg, V., Bücklein, V., Schmidt, C., Schöberl, F., Dimitriadis, K. A., Forbrig, R., Stemmler, H., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000533 · Cited by 15
CAR T-Cell Therapy: Updates in Nursing Management
Baer, B. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.255-258 · Cited by 15
Chávez, J. C., Yassine, F., Sandoval-Sus, J. D., & Kharfan‐Dabaja, M. A. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2020-0021 · Cited by 16
Roider, T., Brinkmann, B. J., Kim, V., Knoll, M., Kolb, C., Roessner, P. M., Bordas, M., Dreger, P., Müller‐Tidow, C., Huber, W. K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005400 · Cited by 15
Dong, R., Jiang, S., Chen, Y., Ma, Y., Sun, L., Xing, C., Zhang, S., & Yu, K. (2021) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0057 · Cited by 16
Siddiqui, R. S., & Sardar, M. R. (2021) · Cureus · doi:10.7759/cureus.14494 · Cited by 15
Optimizing CAR T cell therapy in lymphoma
Qualls, D. A., & Salles, G. A. (2021) · Hematological Oncology · doi:10.1002/hon.2844 · Cited by 16
Mantle cell lymphoma management trends and novel agents: where are we going?
Pu, J. J., Savani, M., Huang, N., & Epner, E. M. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221080743 · Cited by 15
Zurko, J. C., Xu, H., Chaney, K., Schneider, D., Szabó, A., Hari, P., Johnson, B. D., & Shah, N. N. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.011 · Cited by 14
Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
Deshpande, A. J., & Munoz, J. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948513 · Cited by 15
Self-citationTherapeutic Advances in Immunotherapies for Hematological Malignancies
Nogami, A., & Sasaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911526 · Cited by 14
Lew, T. E., Cliff, E. R. S., Dickinson, M. J., Tam, C. S. L., Seymour, J. F., Blombery, P. A., Bajel, A. R., Ritchie, D., & Khot, A. S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2241095 · Cited by 14
de Boer, J., Pennings, E. R. A., Kleinjan, A., van Doesum, J. A., Spanjaart, A. M., Mutsaers, P. G. N. J., Jak, M., van der Poel, M., Kuipers, M. T., Adam, J. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010665 · Cited by 14
Self-citationShumilov, E., Boyadzhiev, H., Mazzeo, P., Akhoundova, D., Daskalakis, M., Novak, U., Lenz, G., Bacher, U., & Pabst, T. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000984 · Cited by 14
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 14
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
Drougkas, K., Karampinos, K. I., Karavolias, I., Gomatou, G., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., & Kotteas, E. A. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01054-2 · Cited by 15
Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 13
Chong, E. A., Penuel, E. M., Napier, E. B., Lundberg, R. K., Budde, L. E., Shadman, M. S., Matasar, M. J., Bartlett, N. L., Flinn, I. W., Bosch, F., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013640 · Cited by 14
Self-citationDíez, B., Calviño, C., Fernández-García, M., Rodriguez-Marquez, P., Rodríguez-Díaz, S., Martínez-Turillas, R., Ceballos, C., Illarramendi, J., Serrano-López, J., Miskey, C., et al. (2025) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2025.101425 · Cited by 12
Gotti, M., Defrancesco, I., D’Angelo, M., Basso, S., Crotto, L., Marinelli, A., Maccalli, C., & Iaconianni, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565236 · Cited by 15
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
Mihályová, J., Hradská, K., Jelı́nek, T., Motais, B., Celichowski, P., & Hájek, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111470 · Cited by 14
Immunotherapy-Related Acute Kidney Injury
Manohar, S., Jhaveri, K. D., & Perazella, M. A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.07.006 · Cited by 14
CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
Sheikh, S., Migliorini, D., & Lang, N. (2022) · Biomedicines · doi:10.3390/biomedicines10081960 · Cited by 14
Cancer Immunotherapy Beyond Checkpoint Blockade
Welty, N. E., & Gill, S. I. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.006 · Cited by 16
Heß, G., Dreyling, M. H., Obéric, L., Giné, E., Zinzani, P. L., Linton, K., Vilmar, A. C., Jerkeman, M., Chen, J. M. H., Ohler, A., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2268228 · Cited by 14
CRISPR Takes the Front Seat in CART-Cell Development
Manriquez-Roman, C., Siegler, E. L., & Kenderian, S. S. (2021) · BioDrugs · doi:10.1007/s40259-021-00473-y · Cited by 15
Dhakal, B., Chhabra, S., Savani, B. N., & Hamadani, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17904 · Cited by 14
Hu, Y., Cao, G., Chen, X., Huang, X., Asby, N. W., Ankenbruck, N., Rahman, A., Thusu, A., He, Y., Riedell, P. A., et al. (2021) · Matter · doi:10.1016/j.matt.2021.09.027 · Cited by 13
Cardiovascular disease and chimeric antigen receptor cellular therapy
Rao, A., Stewart, A. F., Eljalby, M., Ramakrishnan, P., Anderson, L. D., Awan, F. T., Chandra, A., Vallabhaneni, S., Zhang, K., & Zaha, V. G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932347 · Cited by 13
Self-citationPreclinical models for development of immune–oncology therapies
Wang, Y., Shelton, S. E., Kastrunes, G. M., Barbie, D. A., Freeman, G. J., & Marasco, W. A. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.41 · Cited by 14
Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review
Sharma, R., Suravarjhula, L., Banerjee, M., Kumar, G., & Kumar, N. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230220092125 · Cited by 13
Gao, J., Dahiya, S., & Patel, S. A. (2023) · British Journal of Haematology · doi:10.1111/bjh.19001 · Cited by 13
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
Kumar, S. A., Gao, J., & Patel, S. A. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107385 · Cited by 13
Jiang, W., Gu, G., Zhang, Y., Song, Y., Shi, M., Wang, G., Li, H., Tao, T., Qin, J., Li, X., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106942 · Cited by 13
Borogovac, A., & Siddiqi, T. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.001 · Cited by 14
Neuendorff, N. R., Khan, A., Ullrich, F., Yates, S. J., Devarakonda, S. S., Lin, R. J., von Tresckow, B., Córdoba, R., Artz, A. S., & Rosko, A. E. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101734 · Cited by 15
Tri-specific killer engager: unleashing multi-synergic power against cancer
Winidmanokul, P., Panya, A., & Okada, S. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00227 · Cited by 13
FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review
Al‐Ibraheem, A., Abdlkadir, A. S., Lopci, E., Allouzi, S., Páez, D., Alkuwari, M., Ma’koseh, M., Novruzov, F., Usmani, S., Al-Rabi, K. H., et al. (2024) · Cancers · doi:10.3390/cancers16091728 · Cited by 13
Chabannon, C., Ruggeri, A., Montoto, S., van Biezen, A., van der Werf, S. M., Markslag, A., Sánchez‐Ortega, I., de la Cámara, R., Ljungman, P. T., Mohty, M., et al. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101557 · Cited by 15
The Evolving Role of Bridging Therapy during CAR-T Therapy
Bhaskar, S., Dholaria, B., Savani, B. N., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.116261 · Cited by 13
CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations
Xue, B., Liu, Y., Zhou, J., Zhou, L., Ye, S., Lu, Y., Zhang, W., Xiu, B., Liang, A., Lu, Y. C., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.07.011 · Cited by 13
Zhao, L., Yan, F., Tang, D., Li, W., An, N., Ren, C., Wang, Y., Xu, K., & Zhao, K. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07610-3 · Cited by 18
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer
Anupindi, K., Malachowski, J., Hodson, I., Zhu, D., June, C. H., & Levine, B. L. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.010 · Cited by 13
Acharya, U. H., & Walter, R. B. (2020) · Cancers · doi:10.3390/cancers12123617 · Cited by 13
Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma
Komanduri, K. V. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01749 · Cited by 13
Novel Therapies in the Treatment of Hodgkin Lymphoma
Andrade-Gonzalez, X. A., & Ansell, S. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00840-5 · Cited by 13
Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Kharfan‐Dabaja, M. A., Yassine, F., Moustafa, M. A., Iqbal, M., & Murthy, H. S. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.09.004 · Cited by 13
Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas
Sethi, S., Epstein-Peterson, Z. D., Kumar, A. A., & Ho, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739441 · Cited by 14
Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14
Chen, X., Gao, M., An, S., Zhao, L., Han, W., Wan, W., Chen, J., Ma, S., Cai, W., Cao, Y., et al. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102591 · Cited by 13
Spanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., van Meerten, T., van Doesum, J. A., Minnema, M. C., Jak, M., van Dorp, S., et al. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00501 · Cited by 14
Self-citationMa, S., Li, H., Zhou, D., Zhang, X., Shi, M., Cao, J., Qi, Y., Xia, J., Liu, Y., Wang, X., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.011 · Cited by 16
Jain, M. D., Abramson, J. S., & Ansell, S. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473916 · Cited by 11
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 13
García-Vicente, R., Rodríguez-García, A., Ancos-Pintado, R., Arroyo, A., Ortega‐Hernández, A., Bragado-García, I., Castellano, E., Ortiz-Ruiz, A., Navarro-Aguadero, M. Á., Modrego, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1676 · Cited by 12
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead
Shaer, N. S. H. A., Masoud, I., Tleyjeh, A., Al-Attas, A. A., Al-Attas, M. A., Khan, M. I., & Yaqinuddin, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1796675 · Cited by 15
Liu, Y., Yan, F., Jiang, C., Li, Y., Che, Y., McIntosh, J. M., Jordan, A. A., Hou, I., Nie, L., Jin, J., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.282031 · Cited by 12
Self-citation
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
